Research programme: immunomodulators - Swecure

Drug Profile

Research programme: immunomodulators - Swecure

Alternative Names: Bacterial superantigens - Swecure; Staphylococcus aureus superantigen - Swecure; SWE 01; SWE 02; Swe01; Swe02

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator Swecure
  • Class Bacteria; Bacterial proteins
  • Mechanism of Action Immunostimulants; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity; Inflammatory bowel diseases

Most Recent Events

  • 01 Sep 2015 Preclinical trials in Hypersensitivity (Prevention) in Sweden (unspecified route)
  • 01 Sep 2015 Preclinical trials in Inflammatory bowel disease in Sweden (unspecified route)
  • 01 Sep 2015 Swecure has patent protection for use of Swe 01 for the prevention of allergy in children in Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top